Literature DB >> 23264094

Hepatitis B and immigrants: a SIMIT multicenter cross-sectional study.

M Fasano1, A Saracino, G Carosi, F Mazzotta, N Marino, E Sagnelli, G B Gaeta, G Angarano, G Verucchi, P Bellissima, C Angeletti, T Santantonio.   

Abstract

BACKGROUND: The continuing migration of individuals from geographic areas with high/medium endemicity has determined the arrival of new chronic hepatitis B virus (HBV) carriers in Italy. The magnitude of this phenomenon and clinical/virological features of HBsAg-positive migrants remain not very well defined. AIMS: To evaluate the proportion of HBsAg-positive immigrants enrolled in this multicenter Società Italiana di Malattie Infettive e Tropicali (SIMIT) cross-sectional study and to compare the characteristics of chronic hepatitis B infection in migrants to those of Italian carriers.
METHODS: From February 1 to July 31 2008, anonymous data were obtained from all HBsAg-positive patients aged ≥ 18 years observed at 74 Italian centers of infectious diseases.
RESULTS: Of the 3,760 HBsAg-positive subjects enrolled, 932 (24.8 %) were immigrants, with a prevalent distribution in central to northern Italy. The areas of origin were: Far East (37.1 %), Eastern Europe (35.4 %), Sub-Saharan Africa (17.5 %), North Africa (5.5 %), and 4.5 % from various other sites. Compared to Italian carriers, migrants were significantly younger (median age 34 vs. 52 years), predominantly female (57.5 vs. 31 %), and most often at first observation (incident cases 34.2 vs. 13.3 %). HBeAg-positives were more frequent among migrants (27.5 vs. 14 %). Genotype D, found in 87.8 % of Italian carriers, was present in only 40 % of migrants, who were more frequently inactive HBV carriers, with a lower prevalence of chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). Only 27.1 % of migrants received antiviral treatment compared to 50.3 % of Italians.
CONCLUSIONS: Twenty-five percent of all HBV carriers examined at Italian centers was composed of immigrants with demographic, serological, and virological characteristics that differed from those of natives and appeared to have an inferior access to treatment.

Entities:  

Mesh:

Year:  2012        PMID: 23264094     DOI: 10.1007/s15010-012-0384-9

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  18 in total

1.  Factors affecting the compliance of the antenatal hepatitis B screening programme in Italy.

Authors:  Tommaso Stroffolini; Elvira Bianco; Andrè Szklo; Rossana Bernacchia; Crescenzo Bove; Mario Colucci; Rosa Cristina Coppola; Paolo D'Argenio; Pierluigi Lopalco; Antonino Parlato; Pietro Ragni; Andrea Simonetti; Carla Zotti; Alfonso Mele
Journal:  Vaccine       Date:  2003-03-07       Impact factor: 3.641

2.  Evaluation of the compliance with the protocol for preventing perinatal hepatitis B infection in Italy.

Authors:  Enea Spada; Maria Elena Tosti; Ornella Zuccaro; Tommaso Stroffolini; Alfonso Mele
Journal:  J Infect       Date:  2010-12-01       Impact factor: 6.072

3.  Clinical relevance and public health significance of hepatitis B virus genomic variations.

Authors:  Guang-Wen Cao
Journal:  World J Gastroenterol       Date:  2009-12-14       Impact factor: 5.742

4.  [Epidemiologic multicenter study of the prevalence of hepatitis in hospitalised immigrants in Italy in the year 2002].

Authors:  G Scotto; A Saracino; R Pempinello; I El Hamad; S Geraci; E Palumbo; D C Cibelli; G Angarano
Journal:  Ann Ig       Date:  2005 Jan-Feb

5.  The impact of the hepatitis B mass immunisation campaign on the incidence and risk factors of acute hepatitis B in Italy.

Authors:  T Stroffolini; A Mele; M E Tosti; G Gallo; E Balocchini; P Ragni; F Santonastasi; A Marzolini; M Ciccozzi; A Moiraghi
Journal:  J Hepatol       Date:  2000-12       Impact factor: 25.083

Review 6.  The clinical implications of hepatitis B virus genotype: Recent advances.

Authors:  Chih-Lin Lin; Jia-Horng Kao
Journal:  J Gastroenterol Hepatol       Date:  2011-01       Impact factor: 4.029

7.  The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B.

Authors:  Brian J McMahon
Journal:  Hepatol Int       Date:  2008-11-26       Impact factor: 6.047

8.  Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma.

Authors:  Man-Fung Yuen; Erwin Sablon; He-Jun Yuan; Danny Ka-Ho Wong; Chee-Kin Hui; Benjamin Chun-Yu Wong; Annie On-On Chan; Ching Lung Lai
Journal:  Hepatology       Date:  2003-03       Impact factor: 17.425

9.  Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective.

Authors:  Irene K Veldhuijzen; Mehlika Toy; Susan J M Hahné; G Ardine De Wit; Solko W Schalm; Robert A de Man; Jan Hendrik Richardus
Journal:  Gastroenterology       Date:  2009-10-29       Impact factor: 22.682

10.  Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease.

Authors:  Hajime Sumi; Osamu Yokosuka; Naohiko Seki; Makoto Arai; Fumio Imazeki; Tomoko Kurihara; Tatsuo Kanda; Kenichi Fukai; Masaki Kato; Hiromitsu Saisho
Journal:  Hepatology       Date:  2003-01       Impact factor: 17.425

View more
  12 in total

Review 1.  Vaccinations in migrants and refugees: a challenge for European health systems. A systematic review of current scientific evidence.

Authors:  Daniele Mipatrini; Paola Stefanelli; Santino Severoni; Giovanni Rezza
Journal:  Pathog Glob Health       Date:  2017-02-06       Impact factor: 2.894

2.  Access to health services for undocumented immigrants in Apulia.

Authors:  G Brindicci; G Trillo; C R Santoro; A Volpe; L Monno; G Angarano
Journal:  J Immigr Minor Health       Date:  2015-04

3.  Characteristics of US-Born Versus Foreign-Born Americans of African Descent With Chronic Hepatitis B.

Authors:  Mohamed A Hassan; W Ray Kim; Ruosha Li; Coleman I Smith; Michael W Fried; Richard K Sterling; Marc G Ghany; Abdus S Wahed; Lilia M Ganova-Raeva; Lewis R Roberts; Anna S F Lok
Journal:  Am J Epidemiol       Date:  2017-08-01       Impact factor: 4.897

4.  Clinical management of chronic hepatitis B infection: results from a registry at a German tertiary referral center.

Authors:  M Demir; J Nigemeier; F Kütting; A Bowe; C Schramm; V Hoffmann; D Waldschmidt; T Goeser; H-M Steffen
Journal:  Infection       Date:  2015-02-21       Impact factor: 3.553

5.  Clinical, epidemiological and virological features of acute hepatitis B in Italy.

Authors:  Ornella Zuccaro; Luisa Romanò; Alfonso Mele; Andrea Mariano; Massimo Clementi; Maria Elena Tosti; Gloria Taliani; Claudio Galli; Alessandro Remo Zanetti; Enea Spada
Journal:  Infection       Date:  2015-02-20       Impact factor: 3.553

Review 6.  Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy.

Authors:  Evangelista Sagnelli; Caterina Sagnelli; Mariantonietta Pisaturo; Margherita Macera; Nicola Coppola
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

7.  Let It "B"? The role of Hepatitis B universal vaccination among italian problematic drug users.

Authors:  Fabio Lugoboni; Raimondo Maria Pavarin; Chiara Resentera; Daniele Gambini
Journal:  Int J Environ Res Public Health       Date:  2015-04-13       Impact factor: 3.390

8.  Health inequalities: an analysis of hospitalizations with respect to migrant status, gender and geographical area.

Authors:  Chiara de Waure; Stefania Bruno; Giuseppe Furia; Luca Di Sciullo; Serena Carovillano; Maria Lucia Specchia; Salvatore Geraci; Walter Ricciardi
Journal:  BMC Int Health Hum Rights       Date:  2015-02-07

9.  Language support for linguistic minority chronic hepatitis B/C patients: an exploratory study of availability and clinicians' perceptions of language barriers in six European countries.

Authors:  Abby M Falla; Irene K Veldhuijzen; Amena A Ahmad; Miriam Levi; Jan Hendrik Richardus
Journal:  BMC Health Serv Res       Date:  2017-02-20       Impact factor: 2.655

Review 10.  Review of infectious diseases in refugees and asylum seekers-current status and going forward.

Authors:  Andreas Halgreen Eiset; Christian Wejse
Journal:  Public Health Rev       Date:  2017-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.